Binding of anti-membrane-proximal gp41 monoclonal antibodies to CD4-liganded and -unliganded human immunodeficiency virus type 1 and simian immunodeficiency virus virions

Journal of Virology

Volumn 86, Issue 3, 2012, Pages 1820-1831

  Rathinakumar, Ramesh ^a   Dutta, Moumita ^a   Zhu, Ping ^a,c   Johnson, Welkin E ^b   Roux, Kenneth H ^a  

^a FLORIDA STATE UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c INSTITUTE OF BIOPHYSICS   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 41; GOLD NANOPARTICLE; IMMUNOGLOBULIN G; MONOCLONAL ANTIBODY; PROTEIN A;

ANTIGEN BINDING; ARTICLE; BINDING KINETICS; CHIMERA; CONCENTRATION (PARAMETERS); CONJUGATION; CONTROLLED STUDY; ELECTRON MICROSCOPY; HUMAN IMMUNODEFICIENCY VIRUS 1; LIGAND BINDING; LIPID BILAYER; LIPID VESICLE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN INTERACTION; PROTEIN TARGETING; SIMIAN IMMUNODEFICIENCY VIRUS; STAINING; VIRION;

ANTIBODIES, MONOCLONAL; ANTIGENS, CD4; BINDING SITES, ANTIBODY; HIV ENVELOPE PROTEIN GP41; HIV-1; LIGANDS; MICROSCOPY, ELECTRON; SIMIAN IMMUNODEFICIENCY VIRUS; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1; SIMIAN IMMUNODEFICIENCY VIRUS;

EID: 84857069940     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.05489-11     Document Type: Article

References (86)

1. Alam SM, et al. 2007. The role of antibody polyspecificity and lipid reactivity in binding of broadly neutralizing anti-HIV-1 envelope human monoclonal antibodies 2F5 and 4E10 to glycoprotein 41 membrane proximal envelope epitopes. J. Immunol. 178:4424-4435.
2. Alam SM, et al. 2009. Role of HIV membrane in neutralization by two broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 106: 20234-20239.
3. Alfsen A, Bomsel M. 2002. HIV-1 gp41 envelope residues 650-685 exposed on native virus act as a lectin to bind epithelial cell galactosyl ceramide. J. Biol. Chem. 277:25649-25659.
4. Alving CR. 2008. 4E10 and 2F5 monoclonal antibodies: binding specificities to phospholipids, tolerance, and clinical safety issues. AIDS 22: 649-651.
5. Apellániz B, Nir S, Nieva JL. 2009. Distinct mechanisms of lipid bilayer perturbation induced by peptides derived from the membrane-proximal external region of HIV-1 gp41. Biochemistry 48:5320-5331.
6. Binley JM, et al. 2003. Redox-triggered infection by disulfide-shackled human immunodeficiency virus type 1 pseudovirions. J. Virol. 77: 5678-5684.
7. Binley JM, et al. 2008. Profiling the specificity of neutralizing antibodies in a large panel of plasmas from patients chronically infected with human immunodeficiency virus type 1 subtypes B and C. J. Virol. 82: 11651-11668.
8. Binley JM, et al. 2004. Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J. Virol. 78:13232-13252.
9. Bomsel M, et al. 2011. Immunization with HIV-1 gp41 subunit virosomes induces mucosal antibodies protecting nonhuman primates against vaginal SHIV challenges. Immunity 34:269-280.
10. Brown BK, et al. 2007. Monoclonal antibodies to phosphatidylinositol phosphate neutralize human immunodeficiency virus type 1: role of phosphate-binding subsites. J. Virol. 81:2087-2091.
11. Bryson S, Julien JP, Hynes RC, Pai EF. 2009. Crystallographic definition of the epitope promiscuity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5: vaccine design implications. J. Virol. 83:11862-11875.
12. Buchacher A, et al. 1994. Generation of human monoclonal antibodies against HIV-1 proteins: electrofusion and Epstein-Barr virus transformation for peripheral blood lymphocyte immortalization. AIDS Res. Hum. Retrovir. 10:359-369.
13. Cardoso RM, et al. 2005. Broadly neutralizing anti-HIV antibody 4E10 recognizes a helical conformation of a highly conserved fusion-associated motif in gp41. Immunity 22:163-173.
14. Chakrabarti BK, et al. 2011. HIV type 1 env precursor cleavage state affects recognition by both neutralizing and nonneutralizing gp41 antibodies. AIDS Res. Hum. Retrovir. 27:878-887.
15. Chertova E, Jr, et al. 2002. Envelope glycoprotein incorporation, not shedding of surface envelope glycoprotein (gp120/SU), is the primary determinant of SU content of purified human immunodeficiency virus type 1 and simian immunodeficiency virus. J. Virol. 76:5315-5325.
16. Crooks ET, et al. 2005. Characterizing anti-HIV monoclonal antibodies and immune sera by defining the mechanism of neutralization. Hum. Antibodies 14:101-113.
17. Crooks ET, Tong T, Osawa K, Binley JM. 2011. Enzyme digests eliminate non-functional env from HIV-1 particle surfaces leaving native env trimers intact and viral infectivity unaffected. J. Virol. 85:5825-5839.
18. Dennison SM, et al. 2009. Stable docking of neutralizing human immunodeficiency virus type 1 gp41 membrane-proximal external region monoclonal antibodies 2F5 and 4E10 is dependent on the membrane immersion depth of their epitope regions. J. Virol. 83:10211-10223.
19. de Rosny E, Vassell R, Jiang S, Kunert R, Weiss CD. 2004. Binding of the 2F5 monoclonal antibody to native and fusion-intermediate forms of human immunodeficiency virus type 1 gp41: implications for fusioninducing conformational changes. J. Virol. 78:2627-2631.
20. Dhillon AK, et al. 2007. Dissecting the neutralizing antibody specificities of broadly neutralizing sera from human immunodeficiency virus type 1-infected donors. J. Virol. 81:6548-6562.
21. Eckert D, Kim P. 2001. Mechanisms of viral membrane fusion and its inhibition. Annu. Rev. Biochem. 70:777-810.
22. Finnegan CM, Berg W, Lewis GK, DeVico AL. 2002. Antigenic properties of the human immunodeficiency virus transmembrane glycoprotein during cell-cell fusion. J. Virol. 76:12123-12134.
23. Franquelim HG, et al. 2011. Anti-HIV-1 antibodies 2F5 and 4E10 interact differently with lipids to bind their epitopes. AIDS 25:419-428.
24. Frey G, et al. 2008. A fusion-intermediate state of HIV-1 gp41 targeted by broadly neutralizing antibodies. Proc. Natl. Acad. Sci. U. S. A. 105: 3739-3744.
25. Gorny MK, et al. 2005. Identification of a new quaternary neutralizing epitope on human immunodeficiency virus type 1 virus particles. J. Virol. 79:5232-5237.
26. Gray ES, et al. 2009. Broad neutralization of human immunodeficiency virus type 1 mediated by plasma antibodies against the gp41 membrane proximal external region. J. Virol. 83:11265-11274.
27. Gray ES, Meyers T, Gray G, Montefiori DC, Morris L. 2006. Insensitivity of paediatric HIV-1 subtypeCviruses to broadly neutralizing monoclonal antibodies raised against subtype B. PLoS Med. 3:e255.
28. Gray ES, et al. 2007. Neutralizing antibody responses in acute human immunodeficiency virus type 1 subtype C infection. J. Virol. 81: 6187-6196.
29. Gray ES, et al. 2009. Antibody specificities associated with neutralization breadth in plasma from human immunodeficiency virus type 1 subtype C-infected blood donors. J. Virol. 83:8925-8937.
30. Grundner C, Mirzabekov T, Sodroski J, Wyatt R. 2002. Solid-phase proteoliposomes containing human immunodeficiency virus envelope glycoproteins. J. Virol. 76:3511-3521.
31. Mut(e,g) potentiates the human immunodeficiency virus type 1 neutralizing activity of monoclonal antibodies directed against the N-terminal helical repeat of gp41. J. Virol. 82: 10032-10041.
32. Haynes BF, et al. 2005. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308:1906-1908.
33. Ba-L. J. Virol. 84:1302-1313.
34. Honnen WJ, et al. 2007. Type-specific epitopes targeted by monoclonal antibodies with exceptionally potent neutralizing activities for selected strains of human immunodeficiency virus type 1 map to a common region of the V2 domain of gp120 and differ only at single positions from the clade B consensus sequence. J. Virol. 81:1424-1432.
35. Huarte N, et al. 2008. The broadly neutralizing anti-human immunodeficiency virus type 1 4E10 monoclonal antibody is better adapted to membrane-bound epitope recognition and blocking than 2F5. J. Virol. 82:8986-8996.
36. Ingale S, Gach JS, Zwick MB, Dawson PE. 2010. Synthesis and analysis of the membrane proximal external region epitopes of HIV-1. J. Pept. Sci. 16:716-722.
37. Julien JP, Bryson S, Nieva JL, Pai EF. 2008. Structural details of HIV-1 recognition by the broadly neutralizing monoclonal antibody 2F5: epitope conformation, antigen-recognition loop mobility, and anion-binding site. J. Mol. Biol. 384:377-392.
38. Julien JP, et al. 2010. Ablation of the complementarity-determining region H3 apex of the anti-HIV-1 broadly neutralizing antibody 2F5 abrogates neutralizing capacity without affecting core epitope binding. J. Virol. 84:4136-4147.
39. Kang YK, et al. 2009. Structural and immunogenicity studies of a cleaved, stabilized envelope trimer derived from subtype A HIV-1. Vaccine 27: 5120-5132.
40. Klein JS, et al. 2009. Examination of the contributions of size and avidity to the neutralization mechanisms of the anti-HIV antibodies b12 and 4E10. Proc. Natl. Acad. Sci. U. S. A. 106:7385-7390.
41. Leaman DP, Kinkead H, Zwick MB. 2010. In-solution virus capture assay helps deconstruct heterogeneous antibody recognition of human immunodeficiency virus type 1. J. Virol. 84:3382-3395.
42. Lenz O, et al. 2005. Trimeric membrane-anchored gp41 inhibits HIV membrane fusion. J. Biol. Chem. 280:4095-4101.
43. Li M, et al. 2006. Genetic and neutralization properties of subtype C human immunodeficiency virus type 1 molecular env clones from acute and early heterosexually acquired infections in southern africa. J. Virol. 80:11776-11790.
44. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. 2008. Molecular architecture of native HIV-1 gp120 trimers. Nature 455: 109-113.
45. Manrique A, et al. 2007. In vivo and in vitro escape from neutralizing antibodies 2G12, 2F5, and 4E10. J. Virol. 81:8793-8808.
46. Matyas GR, Beck Z, Karasavvas N, Alving CR. 2009. Lipid binding properties of 4E10, 2F5, and WR304 monoclonal antibodies that neutralize HIV-1. Biochim. Biophys. Acta 1788:660-665.
47. Matyas GR, et al. 2009. Neutralizing antibodies induced by liposomal HIV-1 glycoprotein 41 peptide simultaneously bind to both the 2F5 or 4E10 epitope and lipid epitopes. AIDS. 23:2069-2077.
48. Mehandru S, et al. 2004. Neutralization profiles of newly transmitted human immunodeficiency virus type 1 by monoclonal antibodies 2G12, 2F5, and 4E10. J. Virol. 78:14039-14042.
49. Montero M, van Houten NE, Wang X, Scott JK. 2008. The membraneproximal external region of the human immunodeficiency virus type 1 envelope: dominant site of antibody neutralization and target for vaccine design. Microbiol. Mol. Biol. Rev. 72:54-84.
50. Moore JP, McKeating JA, Weiss RA, Sattentau QJ. 1990. Dissociation of gp120 from HIV-1 virions induced by soluble CD4. Science 250: 1139-1142.
51. Moore PL, et al. 2006. Nature of nonfunctional envelope proteins on the surface of human immunodeficiency virus type 1. J. Virol. 80:2515-2528.
52. Mouquet H, et al. 2010. Polyreactivity increases the apparent affinity of anti-HIV antibodies by heteroligation. Nature 467:591-595.
53. Muster T, et al. 1993. A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1. J. Virol. 67:6642-6647.
54. Nelson JD, et al. 2007. An affinity-enhanced neutralizing antibody against the membrane-proximal external region of human-immunodeficiency virus type 1 gp41 recognizes an epitope between those of 2F5 and 4E10. J. Virol. 81: 4033-4043.
55. Nelson JD, et al. 2008. Antibody elicited against the gp41 N-heptad repeat (NHR) coiled-coil can neutralize HIV-1 with modest potency but nonneutralizing antibodies also bind to NHR mimetics. Virology 377: 170-183.
56. Nyambi PN, et al. 2000. Immunoreactivity of intact virions of human immunodeficiency virus type 1 (HIV-1) reveals the existence of fewer HIV-1 immunotypes than genotypes. J. Virol. 74:10670-10680.
57. Ofek G, et al. 2004. Structure and mechanistic analysis of the anti-human immunodeficiency virus type 1 antibody 2F5 in complex with its gp41 epitope. J. Virol. 78:10724-10737.
58. Peachman KK, et al. 2010. The importance of antibody isotype in HIV-1 virus capture assay and in TZM-bl neutralization. Viral Immunol. 23: 627-632.
59. Peachman KK, Wieczorek L, Polonis VR, Alving CR, Rao M. 2010. The effect of sCD4 on the binding and accessibility of HIV-1 gp41 MPER epitopes to human monoclonal antibodies. Virology 408:213-223.
60. Pejchal R, et al. 2009. A conformational switch in human immunodeficiency virus gp41 revealed by the structures of overlapping epitopes recognized by neutralizing antibodies. J. Virol. 83:8451-8462.
61. Poignard P, Fouts T, Naniche D, Moore JP, Sattentau QJ. 1996. Neutralizing antibodies to human immunodeficiency virus type-1 gp120 induce envelope glycoprotein subunit dissociation. J. Exp. Med. 183: 473-484.
62. Poignard P, et al. 2003. Heterogeneity of envelope molecules expressed on primary human immunodeficiency virus type 1 particles as probed by the binding of neutralizing and nonneutralizing antibodies. J. Virol. 77: 353-365.
63. Roux KH, Taylor KA. 2007. AIDS virus envelope spike structure. Curr. Opin. Struct. Biol. 17:244-252.
64. Ruprecht CR, et al. 2011. MPER-specific antibodies induce gp120 shedding and irreversibly neutralize HIV-1. J. Exp. Med. 208:439-454.
65. Sanchez-Martinez S, et al. 2006. Specific phospholipid recognition by human immunodeficiency virus type-1 neutralizing anti-gp41 2F5 antibody. FEBS Lett. 580:2395-2399.
66. Sanchez-Martinez S, Lorizate M, Katinger H, Kunert R, Nieva J. 2006. Membrane association and epitope recognition by HIV-1 neutralizing anti-gp41 2F5 and 4E10 antibodies. AIDS Res. and Hum. Retrovir. 22: 998-1006.
67. Sanders RW, et al. 2002. The mannose-dependent epitope for neutralizing antibody 2G12 on human immunodeficiency virus type 1 glycoprotein gp120. J. Virol. 76:7293-7305.
68. Sather DN, et al. 2009. Factors associated with the development of crossreactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83:757-769.
69. Scherer EM, Leaman DP, Zwick MB, McMichael AJ, Burton DR. 2010. Aromatic residues at the edge of the antibody combining site facilitate viral glycoprotein recognition through membrane interactions. Proc. Natl. Acad. Sci. U. S. A. 107:1529-1534.
70. Scherer EM, Zwick MB, Teyton L, Burton DR. 2007. Difficulties in eliciting broadly neutralizing anti-HIV antibodies are not explained by cardiolipin autoreactivity. AIDS 21:2131-2139.
71. Shen X, et al. 2010. Prolonged exposure of the HIV-1 gp41 membrane proximal region with L669S substitution. Proc. Natl. Acad. Sci. U. S. A. 107:5972-5977.
72. Shen X, et al. 2009. In vivo gp41 antibodies targeting the 2F5 monoclonal antibody epitope mediate human immunodeficiency virus type 1 neutralization breadth. J. Virol. 83:3617-3625.
73. Song L, et al. 2009. Broadly neutralizing anti-HIV-1 antibodies disrupt a hinge-related function of gp41 at the membrane interface. Proc. Natl. Acad. Sci. U. S. A. 106:9057-9062.
74. Tomaras GD, et al. 2008. Initial B-cell responses to transmitted human immunodeficiency virus type 1: virion-binding immunoglobulin M (IgM) and IgG antibodies followed by plasma anti-gp41 antibodies with ineffective control of initial viremia. J. Virol. 82:12449-12463.
75. Vcelar B, et al. 2007. Reassessment of autoreactivity of the broadly neutralizing HIV antibodies 4E10 and 2F5 and retrospective analysis of clinical safety data. AIDS. 21:2161-2170.
76. Veiga AS, Castanho MA. 2006. The membranes role in the HIV-1 neutralizing monoclonal antibody 2F5 mode of action needs re-evaluation. Antivir. Res. 71:69-72.
77. Veiga AS, Pattenden LK, Fletcher JM, Castanho MA, Aguilar MI. 2009. Interactions of HIV-1 antibodies 2F5 and 4E10 with a gp41 epitope prebound to host and viral membrane model systems. Chembiochem. 10: 1032-1044.
78. Vincent N, Genin C, Malvoisin E. 2002. Identification of a conserved domain of the HIV-1 transmembrane protein gp41 which interacts with cholesteryl groups. Biochim. Biophys. Acta 1567:157-164.
79. Vishwanathan SA, Hunter E. 2008. Importance of the membraneperturbing properties of the membrane-proximal external region of human immunodeficiency virus type 1 gp41 to viral fusion. J. Virol. 82: 5118-5126.
80. Yuste E, et al. 2006. Simian immunodeficiency virus engrafted with human immunodeficiency virus type 1 (HIV-1)-specific epitopes: replication, neutralization, and survey of HIV-1-positive plasma. J. Virol. 80: 3030-3041.
81. Zhang G, Lu H, Lu Y, Jiang S, Chen YH. 2005. Neutralization of HIV-1 primary isolate by ELDKWA-specific murine monoclonal antibodies. Immunobiology 210:639-645.
82. Zhou T, et al. 2007. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 445:732-737.
83. Zhu P, et al. 2003. Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions. Proc. Natl. Acad. Sci. U. S. A. 100:15812-15817.
84. Zhu P, et al. 2006. Distribution and three-dimensional structure of AIDS virus envelope spikes. Nature 441:847-852.
85. Zwick MB, et al. 2004. The long third complementarity-determining region of the heavy chain is important in the activity of the broadly neutralizing anti-human immunodeficiency virus type 1 antibody 2F5. J. Virol. 78:3155-3161.
86. Zwick MB, et al. 2001. Broadly neutralizing antibodies targeted to the membrane-proximal external region of human immunodefeciency virus type 1 glycoprotein gp41. J. Virol. 75:10892-10905.